In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Independent mutual fund directors typically attend four quarterly meetings each year, but their board-related work is not confined to those hours spent inside the boardroom. In ...
Amy Lancellotta will retire from the Independent Directors Council at the end of this year after 13 years as managing director and a total of 30 ...
The board overseeing Ariel Funds is among the most diverse in the business, when measured by gender, race, and background/skills. And while it may seem like ...
The Securities and Exchange Commission's Division of Investment Management is planning to launch a new outreach initiative targeted at small and mid-sized fund complexes, an effort ...